Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced a presentation of animal study data on the Myotech Circulatory Support System (CSS) at the 54th annual meeting of the American Society of Artificial Internal Organs (ASAIO) in San Francisco, June 19th – 21st. The data to be presented confirm the effectiveness of the Myotech CSS in supporting whole heart function in a manner not possible with other known systems, and also highlights the value of ultrasound imaging as an adjunct to the CSS.
The Myotech CSS consists of a flexible polymer cup that slips over the heart and connects to an external drive unit to pump the heart and restore normal blood flow. It can be installed in approximately three minutes through a small incision to provide immediate, life-saving support in emergency situations. Since it has no contact with circulating blood, the Myotech CSS is expected to reduce the risk of patient complications, such as clotting and stroke, bleeding, and infection.
In the poster presentation, Myotech Medical Director Mark Anstadt M.D. and his colleagues at Wright State University will show recent data from animal studies where an ultrasound technique called Velocity Vector Imaging (VVI) is used to image the position of the cup on the heart, but also the speed of movement of every section of cardiac tissue, while the heart is being supported by the CSS device. These data clearly indicate the superior performance of the CSS during the critical diastolic (filling) part of the cardiac cycle. Conventional ventricular assist devices cannot provide this level of support for a damaged or failing heart.
The first generation Myotech CSS system is being developed for acute heart failure applications using VVI and other ultrasound methods to refine the design and control of the CSS cup. Future generations of the product may have partially integrated ultrasound capability, making the system easier to optimize for each patient.
“This study supports our expectations regarding the superior performance of the Myotech CSS in providing natural circulatory support under a variety of emergency situations,” stated John Lanzafame, Biophan CEO. “Our initial focus is on acute resuscitation, which will be the initial application of the technology. This study demonstrates that the Myotech CSS augments diastolic function unlike other known devices, which is important in short-term support, but also may be very helpful in longer-term support situations. We are very excited about the potential of this technology platform.”
About Biophan Technologies, Inc.
Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is helping to commercialize the Myotech Circulatory Support System, which has significant potential to improve the treatment of acute heart failure. Biophan Technologies, Inc. holds a 68% interest in Myotech with rights to acquire additional equity, and is leading Myotech’s business development efforts. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan’s actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan’s ability to develop its technologies; the approval of Biophan’s patent applications; the successful implementation of Biophan’s research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology, generally, and in human patients; the acceptance by the market of Biophan’s technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan’s technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this press release should be read in conjunction with Biophan’s periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact: Carolyn Hotchkiss Communications Manager Biophan Technologies, Inc. (585) 267-4800 Email Contact
SOURCE: Biophan Technologies, Inc.
Comments